Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2000

View Archived Issues

Researchers identify new nuclear receptor targets for cholesterol control

Niacin safely controls lipid disorders in diabetic patients

Cantab increases products in clinical development to six during first half 2000

Orally active partial D2 agonist may have potential in PD and schizophrenia

Cel-Sci receives grant for cervical cancer study with Multikine

Promising data reported from phase II trial of injectable anticoagulant

Maxamine scheduled for December advisory panel review

Sangamo establishes collaboration with Merck & Co.

New formulation of Zyprexa introduced for psychotic disorders and manic episodes

Agouron commences additional capravirine clinical trial

FDA approves QVAR Inhalation Aerosol for treatment of asthma

Preclinical activity, pharmacokinetics and toxicity reported for novel parenteral carbapenem

BMS-247243, a new anti-MRSA cephem, debuts at ICAAC

Sankyo presents preclinical profile of promising new triazole antifungal agent

Candidate for Rx of Gram-positive infections selected at Daiichi

ICAAC news: first report of potential anti-flu agent with novel mode of action

First selective orexin-1 receptor antagonists emerge from R&D program at SB

Several related series described by Bayer as useful for anemia Rx

AHP synthesizes and evaluates new PTPase inhibitors

Serotonergic agents, their activity and therapeutic uses disclosed by ADIR

uPAR antagonists claimed by Roche Diagnostics as antitumor/antimetastatic agents

BASF presents new cysteine protease inhibitors and their therapeutic use

New broad-spectrum antibacterial agents derived from erythromycin

Matrix metalloproteinase-inhibitory compounds described in recent patent

Novartis presents new NK1 receptor antagonists with potential for pain and migraine

Therapies for obesity, diabetes under investigation at Dainippon

Elan to acquire Dura

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...